Second phase platelet aggregation induced by adenosine diphosphate in patients with cerebral vascular disease and in control subjects.
D000227:Adenine Nucleotides / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects*; D001991:Bronchitis / Q000097:blood; D002349:Carpal Tunnel Syndrome / Q000097:blood; D002561:Cerebrovascular Disorders / Q000097:blood* / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000097:blood; D004176:Dipyridamole / Q000627:therapeutic use; D004415:Dyspepsia / Q000097:blood; D005260:Female; D006505:Hepatitis / Q000097:blood; D006562:Herpes Zoster / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000097:blood; D007405:Intervertebral Disc Displacement / Q000097:blood; D008297:Male; D008575:Meniere Disease / Q000097:blood; D008875:Middle Aged; D008881:Migraine Disorders / Q000097:blood; D009437:Neuralgia / Q000097:blood; D009497:Neurotic Disorders / Q000097:blood; D010300:Parkinson Disease / Q000097:blood; D010973:Platelet Adhesiveness / Q000187:drug effects; D013128:Spinal Osteophytosis / Q000097:blood; D014277:Trigeminal Neuralgia / Q000097:blood; D014648:Varicose Veins / Q000097:blood; D014777:Virus Diseases / Q000097:blood
D000227:Adenine Nucleotides; D004176:Dipyridamole